Your session is about to expire
← Back to Search
AG-881 for Brain Tumor
Study Summary
This trial is testing a new drug for patients with brain tumors that have a specific genetic mutation.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- If you have gliomas and have previously been treated with bevacizumab (Avastin), you cannot participate in the study.You have a serious infection that needs strong medicine to treat it, or you have a high fever without a clear reason during the screening visits or when you start taking the study drug (unless the doctor thinks your fever is caused by your tumor).You have unstable or uncontrolled chest pain (angina).You have a history of serious and uncontrolled heart rhythm problems.You have difficulty swallowing, have a shortened intestine, or have a condition that affects how your stomach digests food.You have brain metastases that are causing symptoms or need treatment to control symptoms. You have also received radiation, surgery, or other therapies for your brain metastases within the past month.
- Group 1: AG881
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many locales are overseeing this trial?
"Potential participants in this research project can find enrolling sites at various locations, such as UT Southwestern Medical Center Miami, UCLA Oncology Centre New york and Memorial Sloan Kettering Cancer Center Los Angeles. Additionally, there are another 18 hospitals that have been approved to recruit patients for the study."
Does this trial presently have open enrollment?
"According to clinicaltrials.gov, this trial is no longer enrolling participants and has not been actively recruiting since May 16th 2022. However, there are 355 other studies that currently require volunteers."
What potential risks does AG881 pose for individuals who take it?
"The safety of AG881 was rated 1 on our team's scale, due to limited clinical data supporting both its efficacy and safety."
Share this study with friends
Copy Link
Messenger